2023/7/10 12:39 Acute Coronary Syndrome - StatPearls - NCBI Bookshelf

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.

Acute Coronary Syndrome

Anumeha Singh; Abdulrahman S. Museedi; Shamai A. Grossman.

Author Information and Affiliations

Last Update: July 11, 2022.

Continuing Education Activity

Acute coronary syndrome refers to a group of diseases in which blood flow to the heart is
decreases. Some examples include ST-elevation myocardial infarction, non-ST elevation
myocardial infarction, and unstable angina. This activity reviews the evaluation and treatment of
patients with acute coronary syndrome, and highlights the role of the interprofessional team in
caring for these patients.

Objectives:

Identify risk factors for acute coronary syndrome.

Identify how a patient with acute coronary syndrome might present, and describe the
evaluation that should be done.

Describe the treatment of acute coronary syndrome.

Describe the importance of well-coordinated interprofessional teamwork in caring for

patients with acute coronary syndrome.

Access free multiple choice questions on this topic.

Introduction
Acute coronary syndrome (ACS) refers to a group of conditions that include ST-elevation
myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable
angina. It is a type of coronary heart disease (CHD), which is responsible for one-third of total
deaths in people older than 35. Some forms of CHD can be asymptomatic, but ACS is always
symptomatic.[1][2][3]

Etiology
ACS is a manifestation of CHD (coronary heart disease) and usually a result of plaque disruption
in coronary arteries (atherosclerosis). The common risk factors for the disease are smoking,
hypertension, diabetes, hyperlipidemia, male sex, physical inactivity, family obesity, and poor
nutritional practices. Cocaine abuse can also lead to vasospasm. [4][5][6]A family history of
early myocardial infarction (55 years of age) is also a high-risk factor.

Epidemiology
CHD affects about 15.5 million in the United States. The American Heart Association estimates a
person has a heart attack every 41 seconds. Heart disease is the leading cause of death in the
United States. Chest pain is among the top reasons for emergency department visits.

Pathophysiology
The underlying pathophysiology in ACS is decreased blood flow to part of heart musculature
which is usually secondary to plaque rupture and formation of thrombus. Sometimes ACS can be
secondary to vasospasm with or without underlying atherosclerosis. The result is decreased blood
https://www.ncbi.nlm.nih.gov/books/NBK459157/ 1/5
2023/7/10 12:39 Acute Coronary Syndrome - StatPearls - NCBI Bookshelf

flow to a part of heart musculature resulting first in ischemia and then infarction of that part of
the heart.

History and Physical

The classic symptom of ACS is substernal chest pain, often described as crushing or pressure-
like feeling, radiating to the jaw and/or left arm. This classic presentation is not seen always, and
the presenting complaint can be very vague and subtle with chief complaints often being
difficulty breathing, lightheadedness, isolated jaw or left arm pain, nausea, epigastric pain,
diaphoresis, and weakness. Female gender, patients with diabetes, and older age are all
associated with ACS presenting with vague symptoms. A high degree of suspicion is warranted
in such cases.

In the physical exam, general distress and diaphoresis are often seen. Heart sounds are frequently
normal. At times, gallop and murmur can be heard. Lung exam is normal, although at times
crackles may be heard pointing toward associated congestive heart failure (CHF). Bilateral leg
edema may be present indicating CHF. The rest of the systems are typically within normal limits
unless co-pathologies are present. The presence of abdominal tenderness to palpation should
make the provider consider other pathologies like pancreatitis and gastritis. The presence of
unequal pulses warrants consideration of aortic dissection. The presence of unilateral leg
swelling should warrant work-up for pulmonary emboli. Hence a thorough physical exam is very
important to rule out other life-threatening differentials.

Evaluation
The first step of evaluation is an ECG, which helps differentiate between STEMI and NSTEMI
unstable angina. American Heart Association guidelines maintain that any patient with
complaints suspicious of ACS should get an ECG within 10 minutes of arrival. Cath lab should
be activated as soon as STEMI is confirmed in a percutaneous coronary intervention (PCI)
center. Cardiac enzymes especially troponin, CK-MB/CK ratio is important in assessing the
NSTEMI versus myocardial ischemia without tissue destruction. A chest x-ray is useful in
diagnosing causes other than MI presenting with chest pain like pneumonia and pneumothorax.
The same applies for blood work like complete blood count (CBC), chemistry, liver function test,
and lipase which can help differentiate intraabdominal pathology presenting with chest pain.
Aortic dissection and pulmonary emboli should be kept in differential and investigated when the
situation warrants. [7][8][9]

Treatment / Management
The initial treatment for all ACS includes aspirin (300 mg) and heparin bolus and intravenous
(IV) heparin infusion if there are no contraindications to the same. Antiplatelet therapy with
ticagrelor or clopidogrel is also recommended. The choice depends on local cardiologist
preference. Ticagrelor is not given to the patients receiving thrombolysis. [10][11]
[12] Supportive measures like pain control with morphine/ fentanyl and oxygen in case of
hypoxia are provided as required. Nitroglycerin sublingual or infusion can be used for pain relief
as well. In cases of inferior wall ischemia, nitroglycerine can cause severe hypotension and
should be used with extreme caution, if at all. Continuous cardiac monitoring for arrhythmia is
warranted. Further Treatment of ACS depends on whether it is a STEMI /NSTEMI or unstable
angina. The American Heart Association (AHA) recommends an emergent catheterization and
percutaneous intervention (PCI) for STEMI with door to procedure start time of fewer than 90
minutes. A thrombolytic (tenecteplase or other thrombolytic) is recommended if there is no PCI
available and the patient cannot be transferred to the catheterization lab in less than 120 minutes.
AHA guideline dictates the door to needle (TNK/other thrombolytics) time to be less than 30
minutes.

https://www.ncbi.nlm.nih.gov/books/NBK459157/ 2/5
2023/7/10 12:39 Acute Coronary Syndrome - StatPearls - NCBI Bookshelf

NSTEMI/Unstable Angina-Symptom control is tried along with the initial treatment with aspirin,
and heparin. If the patient continues to have pain, then urgent catheterization is recommended. If
symptoms are controlled effectively, then a decision can be made for the timing of
catheterization and other evaluation techniques including myocardial perfusion study from case
to case basis depending on comorbidities. ACS always warrants admission and emergent
cardiology evaluation. Computerized tomography angiography might also be utilized for further
workup depending on availability and cardiologist preference.

Beta-blockers, statin, and ACE inhibitors should be initiated in all ACS cases as quickly as
possible unless contraindications exist. Cases not amenable to PCI are taken for CABG
(coronary artery bypass graft) or managed medically depending upon comorbidities and patient
choice.

Differential Diagnosis

Acute pericarditis

Anxiety disorders

Aortic stenosis

Asthma

Dilated cardiomyopathy

Emergent treatment of gastroenteritis

Esophagitis

Hypertensive emergencies in emergency medicine

Myocardial infarction

Myocarditis

Pearls and Other Issues

Coronary heart disease and acute coronary syndrome remain widely prevalent and still is the top
cause of death in people over 35 years of age. It is essential that providers all over the world
maintain a high degree of suspicion and vigilance while assessing patients with possible ACS.
Along with this, public education and recognition of symptoms are crucial. Another important
aspect of controlling this disease is public education about lifestyle modification and making
people aware of healthier life choices. A critical aspect of STEMI and ACS timely treatment
depends on adequate emergency medical services availability and training. Another crucial step
of ACS control and prevention is education about lifestyle modification including smoking
cessation, regular physical activity, and dietary modifications. Only through this multi-prong
approach can practitioners control this high mortality disease.

Enhancing Healthcare Team Outcomes

ACS is associated with very high morbidity and mortality and is best managed by an
interprofessional team that includes the emergency department physician, cardiologist, internist,
pharmacist, and primary caregivers. The condition is primarily managed by the cadiologist but
the prevention is managed by the primary care provider and nurse practitioner. The patient
should be urged to stop smoking, maintain a healthy body weight, exercise regularly and remain
compliant with the medications. The outlook for patients who are treated promptly is good but

https://www.ncbi.nlm.nih.gov/books/NBK459157/ 3/5
2023/7/10 12:39 Acute Coronary Syndrome - StatPearls - NCBI Bookshelf

those with severe disease and non-compliance have high morbidity including premature death.
[13][14][15] (Level V)

Review Questions

Access free multiple choice questions on this topic.

Comment on this article.

References
1. Zègre-Hemsey JK, Asafu-Adjei J, Fernandez A, Brice J. Characteristics of Prehospital
Electrocardiogram Use in North Carolina Using a Novel Linkage of Emergency Medical
Services and Emergency Department Data. Prehosp Emerg Care. 2019 Nov-Dec;23(6):772-
779. [PMC free article: PMC6751030] [PubMed: 30885071]
2. Alomari M, Bratton H, Musmar A, Al Momani LA, Young M. Ticagrelor-induced Diarrhea in
a Patient with Acute Coronary Syndrome Requiring Percutaneous Coronary Artery
Intervention. Cureus. 2019 Jan 12;11(1):e3874. [PMC free article: PMC6414296] [PubMed:
30899625]
3. Kerneis M, Nafee T, Yee MK, Kazmi HA, Datta S, Zeitouni M, Afzal MK, Jafarizade M,
Walia SS, Qamar I, Pitliya A, Kalayci A, Al Khalfan F, Gibson CM. Most Promising
Therapies in Interventional Cardiology. Curr Cardiol Rep. 2019 Mar 13;21(4):26. [PubMed:
30868280]
4. Bracey A, Meyers HP. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr
7, 2023. Posterior Myocardial Ischemia. [PubMed: 30860754]
5. Voudris KV, Kavinsky CJ. Advances in Management of Stable Coronary Artery Disease: the
Role of Revascularization? Curr Treat Options Cardiovasc Med. 2019 Mar 11;21(3):15.
[PubMed: 30854580]
6. Pop C, Matei C, Petris A. Anticoagulation in Acute Coronary Syndrome: Review of Major
Therapeutic Advances. Am J Ther. 2019 Mar/Apr;26(2):e184-e197. [PubMed: 30839367]
7. Luciano LSC, Silva RLD, Londero Filho OM, Waldrich L, Panata L, Trombetta AP, Preve
JC, Fattah T, Giuliano LC, Thiago LEKS. Analysis of the Appropriate Use Criteria for
Coronary Angiography in Two Cardiology Services of Southern Brazil. Arq Bras Cardiol.
2019 May;112(5):526-531. [PMC free article: PMC6555578] [PubMed: 30892387]
8. Campanile A, Castellani C, Santucci A, Annunziata R, Tutarini C, Reccia MR, Del Pinto M,
Verdecchia P, Cavallini C. Predictors of in-hospital and long-term mortality in unselected
patients admitted to a modern coronary care unit. J Cardiovasc Med (Hagerstown). 2019
May;20(5):327-334. [PubMed: 30865139]
9. Chen WWC, Law KK, Li SK, Chan WCK, Cheong A, Fong PC, Hung YT, Lai SWK, Leung
GTC, Wong EML, Wong RWK, Yan CT, Yan VWT, Au Yeong TCK. Extended dual
antiplatelet therapy for Asian patients with acute coronary syndrome: expert
recommendations. Intern Med J. 2019 Mar;49 Suppl 1:5-8. [PubMed: 30815979]
10. Duarte GS, Nunes-Ferreira A, Rodrigues FB, Pinto FJ, Ferreira JJ, Costa J, Caldeira D.
Morphine in acute coronary syndrome: systematic review and meta-analysis. BMJ Open.
2019 Mar 15;9(3):e025232. [PMC free article: PMC6429865] [PubMed: 30878985]
11. Gilutz H, Shindel S, Shoham-Vardi I. Adherence to NSTEMI Guidelines in the Emergency
Department: Regression to Reality. Crit Pathw Cardiol. 2019 Mar;18(1):40-46. [PubMed:
30747764]
12. Klein MD, Williams AK, Lee CR, Stouffer GA. Clinical Utility of CYP2C19 Genotyping to
Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing
Percutaneous Coronary Intervention. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):647-
652. [PubMed: 30760018]
13. Abdur Rehman K, Wazni OM, Barakat AF, Saliba WI, Shah S, Tarakji KG, Rickard J,
Bassiouny M, Baranowski B, Tchou PJ, Bhargava M, Dresing TJ, Callahan TD, Cantillon
https://www.ncbi.nlm.nih.gov/books/NBK459157/ 4/5
2023/7/10 12:39 Acute Coronary Syndrome - StatPearls - NCBI Bookshelf

DJ, Chung M, Kanj M, Irefin S, Lindsay B, Hussein AA. Life-Threatening Complications

of Atrial Fibrillation Ablation: 16-Year Experience in a Large Prospective Tertiary Care Cohort.
JACC Clin Electrophysiol. 2019 Mar;5(3):284-291. [PubMed: 30898229]
14. Xia K, Wang LF, Yang XC, Jiang HY, Zhang LJ, Yao DK, Hu DY, Ding RJ. Comparing the
effects of depression, anxiety, and comorbidity on quality-of-life, adverse outcomes, and
medical expenditure in Chinese patients with acute coronary syndrome. Chin Med J (Engl).
2019 May 05;132(9):1045-1052. [PMC free article: PMC6595882] [PubMed: 30896567]
15. Ahn KT, Seong SW, Choi UL, Jin SA, Kim JH, Lee JH, Choi SW, Jeong MH, Chae SC,
Kim YJ, Kim CJ, Kim HS, Cho MC, Gwon HC, Jeong JO, Seong IW., Korea Acute
Myocardial Infarction Registry - National Institute of Health (KAMIR-NIH) Investigators.
Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel
in type 2 diabetes patients with acute myocardial infarction underwent successful
percutaneous coronary intervention. Medicine (Baltimore). 2019 Mar;98(11):e14833. [PMC
free article: PMC6426627] [PubMed: 30882670]
Disclosure: Anumeha Singh declares no relevant financial relationships with ineligible companies.

Disclosure: Abdulrahman Museedi declares no relevant financial relationships with ineligible companies.

Disclosure: Shamai Grossman declares no relevant financial relationships with ineligible companies.

Copyright © 2023, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0
International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to
distribute the work, provided that the article is not altered or used commercially. You are not required to obtain
permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK459157 PMID: 29083796

https://www.ncbi.nlm.nih.gov/books/NBK459157/ 5/5